Zolpidem
Ambien · Zolpimist
Non-Benzodiazepine HypnoticSchedule IVGeneric availableTDM data
Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.
Compare Zolpidem →FDA-Approved Indications
- Insomnia — short-term, sleep-initiation difficulty (adults)
Common Off-Label Uses
- Disorders of consciousness (investigational)
- Catatonia (case reports)
What Sets This Drug Apart
- Selective GABA-A alpha-1 agonist — more receptor-selective than eszopiclone or benzodiazepines; rapid onset (~15-30 min)
- Short half-life (2.5h) makes it best for sleep onset; less effective for sleep maintenance unless using ER formulation
- Complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating) carry FDA boxed warning — risk with any dose, especially with alcohol or CNS depressants
- Multiple formulations: IR tablet, ER tablet, sublingual (Edluar, Intermezzo for middle-of-night awakening), oral spray (Zolpimist)
- Women require lower starting dose (5 mg) than men due to slower clearance and higher next-day impairment risk
Boxed Warning
COMPLEX SLEEP BEHAVIORS